BNF 72 (British National Formulary September 2016-March 2017)
Seiten
2016
|
72nd Revised edition
Pharmaceutical Press (Verlag)
978-0-85711-273-6 (ISBN)
Pharmaceutical Press (Verlag)
978-0-85711-273-6 (ISBN)
- Titel erscheint in neuer Auflage
- Artikel merken
Zu diesem Artikel existiert eine Nachauflage
The September 2016 British National Formulary (BNF 72) is your essential reference book for prescribing, dispensing, and administering medicines.
The September 2016 British National Formulary (BNF 72) provides up-to-date, practical guidance on prescribing, dispensing, and administering medicines. This essential reference reflects current best practice as well as legal and professional guidelines relating to the uses of medicines.
BNF 72 has been revised and revalidated to reflect changes in product availability, emerging safety concerns and shifts in clinical practice. Access to the latest edition of the BNF is vital for healthcare professionals, as there are a large number of updates from one edition to the next.
Some of the significant content updates for BNF 72 include:
New safety information about the risk of abnormal pregnancy outcomes with sodium valproate and valproic acid
Updated guidance for conditions including asthma, obesity, coeliac disease, irritable bowel syndrome and prostate cancer
New drug monographs including edoxaban, albiglutide, dulaglutide, dasabuvir, and vortioxetine
Updated pregnancy-prevention advice for patients taking mycophenolate mofetil
Updated guidance on the risk of hepatitis B reactivation with BCR-ABL tyrosine kinase inhibitors, and pomalidomide
Advice about the risk of ulceration with nicorandil treatment
NICE guidelines including the use of vedolizumab for treating moderately to severely active Crohn’s disease
New guidance on suspected or confirmed drug allergy
Evidence grading of BNF recommendations.
The September 2016 British National Formulary (BNF 72) provides up-to-date, practical guidance on prescribing, dispensing, and administering medicines. This essential reference reflects current best practice as well as legal and professional guidelines relating to the uses of medicines.
BNF 72 has been revised and revalidated to reflect changes in product availability, emerging safety concerns and shifts in clinical practice. Access to the latest edition of the BNF is vital for healthcare professionals, as there are a large number of updates from one edition to the next.
Some of the significant content updates for BNF 72 include:
New safety information about the risk of abnormal pregnancy outcomes with sodium valproate and valproic acid
Updated guidance for conditions including asthma, obesity, coeliac disease, irritable bowel syndrome and prostate cancer
New drug monographs including edoxaban, albiglutide, dulaglutide, dasabuvir, and vortioxetine
Updated pregnancy-prevention advice for patients taking mycophenolate mofetil
Updated guidance on the risk of hepatitis B reactivation with BCR-ABL tyrosine kinase inhibitors, and pomalidomide
Advice about the risk of ulceration with nicorandil treatment
NICE guidelines including the use of vedolizumab for treating moderately to severely active Crohn’s disease
New guidance on suspected or confirmed drug allergy
Evidence grading of BNF recommendations.
Erscheinungsdatum | 23.09.2016 |
---|---|
Reihe/Serie | British National Formulary |
Verlagsort | London |
Sprache | englisch |
Maße | 148 x 210 mm |
Themenwelt | Medizin / Pharmazie ► Medizinische Fachgebiete ► Pharmakologie / Pharmakotherapie |
Medizin / Pharmazie ► Pflege | |
Medizin / Pharmazie ► Pharmazie ► PTA / PKA | |
ISBN-10 | 0-85711-273-2 / 0857112732 |
ISBN-13 | 978-0-85711-273-6 / 9780857112736 |
Zustand | Neuware |
Haben Sie eine Frage zum Produkt? |
Mehr entdecken
aus dem Bereich
aus dem Bereich
Arzneimittelverzeichnis für Deutschland (einschließlich …
Buch | Hardcover (2024)
Rote Liste Service GmbH (Verlag)
CHF 149,95
Englisch für Apotheker und PTAs
Buch | Spiralbindung (2024)
Kohlhammer (Verlag)
CHF 44,75